Eli Lilly (LLY)
963.33
+28.73 (3.07%)
NYSE · Last Trade: May 1st, 5:42 PM EDT

Major M&A deals this week include: Eli Lilly buys Profluent for $2.2 billion, Lazard buys Campbell Lutyens, FreshRealm bankruptcy.
Via Benzinga · May 1, 2026
Via MarketBeat · May 1, 2026
The prescription data collected for Eli Lilly's new weight-loss pill, Foundayo, is flawed, analysts said Friday.
Via Investor's Business Daily · May 1, 2026
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.3% in the morning session after the stock continued to rally as the comp...
Via StockStory · May 1, 2026
Via MarketBeat · May 1, 2026
Eli Lilly (NYSE:LLY) Shatters Q1 Expectations with Blowout Earnings Beatchartmill.com
Via Chartmill · April 30, 2026
Eli Lilly stock jumps on strong Q1 performance numbers, with its GLP-1s leading the chart.
Via Barchart.com · May 1, 2026
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 55.5% year on year to $19...
Via StockStory · May 1, 2026
Gary Black calls Eli Lilly's valuation 'compelling' as Q1 earnings soar, driven by the consumer 'love affair' with GLP-1 weight loss drugs.
Via Benzinga · May 1, 2026
Via Benzinga · April 30, 2026
Eli Lilly stock rallies as GLP-1 sales drive a 56% year-on-year increase in Q1 revenue. Jim Cramer recommends buying LLY shares as the weight-loss addressable market is truly huge.
Via Barchart.com · April 30, 2026
Thursday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · April 30, 2026
In today's session, there are S&P500 stocks with remarkable trading volume.chartmill.com
Via Chartmill · April 30, 2026
Eli Lilly (LLY) Q1 2026 Earnings Transcript
Via The Motley Fool · April 30, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · April 30, 2026

GLP-1 drugs turned Lilly into a powerhouse. Now it's time to write the next chapter -- in cancer.
Via The Motley Fool · April 30, 2026
Eli Lilly beats Q1 estimates, lifts 2026 outlook as Mounjaro and Zepbound demand offsets pricing pressure and drives strong revenue growth.
Via Benzinga · April 30, 2026
These S&P500 stocks are gapping in today's sessionchartmill.com
Via Chartmill · April 30, 2026
Eli Lilly stock popped early Thursday after the drugmaker crushed first-quarter sales forecasts and hiked its 2026 guidance.
Via Investor's Business Daily · April 30, 2026
Discover the top S&P500 movers in Thursday's pre-market session.chartmill.com
Via Chartmill · April 30, 2026
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 55.5% year on year to ...
Via StockStory · April 30, 2026
The biotech's candidate may treat a great number of illnesses that have one thing in common.
Via The Motley Fool · April 30, 2026
Eli Lilly & Co. (LLY) will release Q1 earnings on April 30. Analysts expect $6.79/share, up from $3.34/share last year. LLY down 2.6% on Wed.
Via Benzinga · April 30, 2026
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results this Thursday before market hours. Here’s what to expect. Eli Lilly beat analyst...
Via StockStory · April 28, 2026

And he may be right.
Via The Motley Fool · April 28, 2026